- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of Topical Prostaglandin Analogue not Associated with Risk of Spontaneous Abortion
![Use of Topical Prostaglandin Analogue not Associated with Risk of Spontaneous Abortion Use of Topical Prostaglandin Analogue not Associated with Risk of Spontaneous Abortion](https://medicaldialogues.in/h-upload/2022/04/29/750x450_175285-download-7.webp)
Prostaglandin analogue use is not associated with the risk of spontaneous abortion, according to a recent study published in the JAMA Ophthalmology.
Recent case reports suggest the use of topical prostaglandin analogues (PGAs) might increase the risk of spontaneous abortions in pregnant people who take these drugs for intraocular pressure control. However, because these reports are derived mainly from voluntary adverse drug reaction databases, they might be prone to reporting bias. A study was conducted to examine the risk of spontaneous abortions among pregnant people who take topical PGAs.
The PharMetrics Plus database (IQVIA) for health claims in the United States from 2006 to 2020 was used as the data source. The percentage of spontaneous abortions was quantified among patients aged 15 to 45 years who were pregnant and took a topical PGA medication during this period compared with a random sample of people in the database not taking a PGA agent. Diagnosis of spontaneous abortion was ascertained through procedure codes or codes from the International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision.
The results of the study are:
- A total of 3881 people of reproductive age who were prescribed PGAs and 3881 control participants not taking PGAs were identified.
- Among the 3881 patients in the PGA cohort, 261 were pregnant and 26 had a spontaneous abortion code.
- Among the 26 individuals, 12 (4.6%) had a spontaneous abortion code within 90 days of the pregnancy code and had an overlapping prescription for a PGA. Among the 12 individuals, 5 (41.7%) were in the age category 40 to 45 years.
- In the control group, there were 801 pregnancies, 56 of which led to spontaneous abortions (7%), resulting in an increased risk of 2.4% (95% CI, −0.7% to 5.4%; P = .17).
Thus, the results of this case-series study suggest no association between use of PGAs and risk of spontaneous abortions. Given the nature of this study design and the potential for unmeasured confounding factors, these results could be explored further in future epidemiologic studies that can better control for potential confounding variables and more accurately ascertain spontaneous abortions through perinatal databases.
Reference:
Association of Topical Prostaglandin Analogue Use With Risk of Spontaneous Abortion by Mahyar Etminan, et al. published in the JAMA Ophthalmology.
doi:10.1001/jamaophthalmol.2022.0628
Keywords:
Prostaglandin, analogue, use, associated, risk, spontaneous abortion, intraocular pressure, glaucoma, Mahyar Etminan, Lindsay Richter, Mohit Sodhi, Frederick S. Mikelberg
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751